The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 44 | — | 20.3x | Near average | |
Growth | 61 | 1028.7% | 5.6% | Near average | |
Quality | 45 | -16.0% | 7.6% | Near average | |
Safety | 22 | 0.6x | 0.4x | Below average | |
Capital Return | 89 | — | 2.15% | Above average | |
Momentum | 71 | — | — | Above average | |
Sentiment | 48 | — | — | Near average |
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
Lexicon Pharmaceuticals, Inc. (LXRX) is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted, innovative treatments for chronic diseases. The company's business model and revenue generation are based on the commercialization of its proprietary pharmaceutical products, entering into licensing and strategic collaboration agreements with major global pharmaceutical companies such as Viatris and Novo Nordisk, under which it receives payments upon achieving specified developmental milestones, in addition to sales revenues of its approved drug INPEFA for the treatment of heart failure.
During the first quarter of 2026, the company achieved a qualitative leap in its financial results, with total revenues reaching $21.1 million compared to $1.3 million in the corresponding quarter of 2025. This growth was driven primarily by the company's recognition of two milestone payments of $20 million ($10 million each) under the licensing agreement with Novo Nordisk, alongside net sales of INPEFA amounting to $1.1 million. Thanks to operational discipline, the net loss decreased sharply to just $1.0 million (or $0 earnings per share) compared to a net loss of $25.3 million in the first quarter of 2025.
Lexicon Pharmaceuticals stock is currently trading at $1.91, which is significantly below the average analyst price target of $6 (with the forecast range spanning from a low of $6 to a high of $6). The current analyst consensus reflects a "Hold" recommendation on the stock, indicating market anticipation for the outcomes of upcoming regulatory and clinical milestones in the second half of the year.
The company ended the first quarter of 2026 with cash, cash equivalents, and short-term investments of $199.7 million, compared to $125.2 million at the end of 2025. This increase is mainly attributed to the successful capital increase round completed in February 2026 and the signing of a new debt financing agreement. The company also managed to reduce its quarterly net loss to just $1.0 million thanks to exceptional partnership revenues realized during the quarter amounting to $21.1 million.
The company plans to resubmit the New Drug Application (NDA) for Zynquista for the treatment of type 1 diabetes by mid-2026. Management is engaged in ongoing and constructive discussions with the U.S. Food and Drug Administration (FDA) to define the final details of the submission. Based on the progress of these discussions and the STENO1 study data, the company expects the potential to obtain final approval and begin commercialization as early as 2026.
The global Phase 3 SONATA study for the treatment of hypertrophic cardiomyopathy (HCM) is progressing excellently and according to the scheduled timeline. The study targets the enrollment of approximately 500 symptomatic patients in both obstructive and non-obstructive types across 130 clinical sites in 20 countries. The company expects to fully complete patient enrollment by mid-2026, with the publication of the study's topline data and results expected in the first quarter of 2027.
Automated analysis for informational purposes only — not investment advice.
The company has an active licensing agreement with Novo Nordisk to develop LX9851, an oral inhibitor for the treatment of obesity and related metabolic disorders. In March 2026, Novo Nordisk initiated a Phase 1 clinical study for this drug, which triggered a second milestone payment to Lexicon of $10 million. This payment was included in the first quarter revenues of 2026, along with another similar $10 million payment recognized under the same agreement.